Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 14/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 13/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 13/20 | 0.57 |
| ▸ | ACACB | O00763 | 4/20 | 0.54 |
| ▸ | AQP1 | P29972 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | NPY4R | P50391 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ACACA | Q13085 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13796958 | 1.00 | NPY5R (0.57) | NPY5RMCHR1ADRA2AACACBAQP1 | |
| SCHEMBL13795911 | 0.92 | NPY5R (0.57) | NPY5RMCHR1ADRA2AACACBAQP1 | |
| SCHEMBL13796978 | 0.91 | MCHR1 (0.70) | NPY5RMCHR1ADRA2AACACB | |
| SCHEMBL13796356 | 0.91 | ACACB (0.54) | NPY5RMCHR1ADRA2AACACBAQP1 | |
| SCHEMBL13796360 | 0.90 | ACACB (0.52) | NPY5RMCHR1ADRA2AACACBAQP1 | |
| SCHEMBL13796969 | 0.90 | ACACB (0.56) | NPY5RMCHR1ADRA2AACACBAQP1 | |
| SCHEMBL8901585 | 0.90 | NPY5R (0.61) | NPY5RMCHR1ADRA2AACACBAQP1 | |
| SCHEMBL14606731 | 0.90 | NPY5R (0.61) | NPY5RMCHR1ADRA2AACACBAQP1 | |
| SCHEMBL8901589 | 0.90 | NPY5R (0.61) | NPY5RMCHR1ADRA2AACACBAQP1 | |
| SCHEMBL13796955 | 0.89 | ACACB (0.55) | NPY5RMCHR1ADRA2AACACBAQP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | MCHR1, MCHR2, MC4R | NPY5R 11/4885MCHR1 1/4885ADRA2A 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.